LJM716

DRUG5 trials

Sponsors

Novartis Pharmaceuticals, Memorial Sloan Kettering Cancer Center

Conditions

Advanced HER2-positive Breast Cancer or Gastric CancerBreast CancerEsophageal Squamous Cell CarcinomaHER2 + Breast CancerHER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaHER2 + Gastric CancerHead and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neck

Phase 1

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

CompletedNCT01598077

Novartis PharmaceuticalsEsophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma +2

Start: 2012-07-31End: 2014-03-31Updated: 2020-12-19

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

CompletedNCT01602406

Novartis PharmaceuticalsAdvanced HER2-positive Breast Cancer or Gastric Cancer

Start: 2012-09-21End: 2017-08-02Updated: 2020-12-19

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

CompletedNCT01822613

Novartis PharmaceuticalsEsophageal Squamous Cell Carcinoma

Start: 2013-07-26End: 2016-06-03Updated: 2020-12-19

Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

WithdrawnNCT02143622

Novartis PharmaceuticalsHead and Neck Squamous Cell Carcinoma

Start: 2015-03-31End: 2018-08-31Updated: 2016-04-21

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

CompletedNCT02167854

Memorial Sloan Kettering Cancer CenterBreast Cancer

Start: 2014-06-16End: 2021-07-07Updated: 2021-07-09

Related Papers

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

2017-09-1224 citations

LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.

2016-12-0911 citations

Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).

Journal of Clinical Oncology2015-05-2027 citations

A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer.

Journal of Clinical Oncology2014-05-2016 citations

A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.

Journal of Clinical Oncology2014-05-2015 citations